Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2025
In 2025, the estimated total EU incidence of meticillin-resistant Staphylococcus aureus (MRSA) bloodstream infections was 4.56 per 100 000 population (EU country range 0.58−12.07). This was 19% lower than in 2019 (baseline year) and 0.23 per 100 000 population lower than the 2030 target of 4.79 per 100 000 population. For the EU overall, a statistically significant decreasing trend was detected between 2019 (baseline year) and 2025, although in the last two years the estimated incidence has been increasing.
Progress towards EU targets on antimicrobial resistance
The estimated total EU incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections in 2025 was 12.13 per 100 000 population (EU country range 3.40−24.61). This was 16.4% higher than in 2019 (baseline year) and 2.75 per 100 000 population higher than the 2030 target of 9.38 per 100 000 population. For the EU overall, no statistically significant trend was detected between 2019 (baseline year) and 2025, although in the last two years the estimated incidence has been higher than in 2019.
The estimated total EU incidence of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in 2025 was 3.75 per 100 000 population (EU country range 0.00−21.29). This was 72% higher than in 2019 (baseline year) and 1.68 per 100 000 population higher than the 2030 target of 2.07 per 100 000 population. For the EU overall, a statistically significant increasing trend was detected between 2019 (baseline year) and 2025.
In summary, while the EU target for the incidence of MRSA bloodstream infections had been reached by 2025, the results for the other two EU targets were not on track. The estimated EU incidence of third-generation cephalosporin-resistant E. coli bloodstream infections with a 10% reduction target had increased by more than 15% compared to 2019 (baseline year). Moreover, the estimated EU incidence of carbapenem-resistant K. pneumoniae bloodstream infections increased by over 70% compared to 2019, which differs substantially from the target of a 5% reduction by 2030.
Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2025
English (1.47 MB - PDF)EARS-Net AER All Countries 2026
English (1.8 MB - PDF)Read the press release
Read about the campaign and see all materials